Company

Idera Pharmaceuticals, Inc.

Headquarters: Exton, PA, United States

Employees: 32

CEO: Mr. Vincent J. Milano

NASDAQ: IDRA

Market Cap

$26.5 Million

USD as of Jan. 1, 2023

Market Cap History

Idera Pharmaceuticals, Inc. market capitalization over time

Evolution of Idera Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Idera Pharmaceuticals, Inc.

Detailed Description

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Idera Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: NASDAQ: IDRA wb_incandescent

Stock: FSX: HXXB wb_incandescent

Details

Headquarters:

505 Eagleview Boulevard

Suite 212

Exton, PA 19341

United States

Phone: 484 348 1600

Fax: 484 348 1670